Creating the Future of Digital Health, Together
Sway Ventures and Nex Cubed, in partnership with Boehringer Ingelheim Ventures, and Aptar, hosted a one-of-a-kind ecosystem event for the health industry exploring the impact of artificial intelligence, machine learning and big data. We’re on a mission to solve the most pressing problems facing healthcare today and actualize the most promising opportunities to reduce cost, enhance quality, and improve outcomes.
This private event, which took place after the JP Morgan Healthcare Conference, brought together senior leaders across health information and technology professionals, payers, providers, investors, fast-growing startups, pharma, policymakers and innovation centers to ask one question: how do we create the future of digital health?
Delivery of Care
Our nation is burdened by healthcare costs, representing nearly 20% of our GDP. These costs show no signs of slowing down given our aging population and longer life expectancy, which is compounded by three in four Americans aged 65 and older managing multiple chronic conditions. Historically, regulation has limited technology permeating into the healthcare industry, but advancements in secure health-tracking/wearables, data processing, and machine learning has connected patients to their health in a way unlike anything we have seen in the past. Patients are now demanding higher quality, affordable and accessible care, resulting in unique opportunities for technology to change the delivery of care. How? That is the question we will be discussing here.
Iana Dimkova, Director of Investing at GE Ventures
Sai Shankar, Vice President, Global Digital Healthcare Systems at Aptar
Moderated by Bill Malloy, Founding General Partners at Sway Ventures
The Future of Pharma Development & Clinical Trials
Pharmaceutical companies spend over $172 billion on research and development on an annual basis. However, of molecules discovered using traditional techniques, 90%+ fail in human clinical trials. Of newly approved drugs 75% are unable to cover the cost of development, and some analysis predict that ROI in pharmaceutical R&D may hit zero by 2020. How is all this possible? When will this industry reap the benefits of new technology? What are those technologies? All of this will be discussed here.
David Kim, Managing Director at DigiTx
Kim Walpole, Co-Founder, CEO at Trials.AI
George Nicola, Co-Founder, CTO at Repurpose.AI
Moderated by Daniel Haders, Managing Director of Healthcare Technology at Nex3 & Operating Partner at Sway Ventures
Exploring the Digital Transformation of Healthcare
What are the technologies that will service this demand? Who are the drivers of its adoption? These questions and more will be discussed here.
Debbie Lin, Executive Director at Boehringer Ingelheim Venture Fund
Daniel van den Bergh, Principal at Kaiser Permanente Venture Fund
Alexis Ji, Partner at Illumina Ventures
Moderated by Daniel Haders, Managing Director of Healthcare Technology at Nex3 & Operating Partner at Sway Ventures
